BlackRock
NRIX icon

BlackRock’s Nurix Therapeutics NRIX Stock Holding History

BlackRock’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213M Sell
8,770,349
-155,293
-2% -$2.65M ﹤0.01% 1761
2026
Q1 		$138M Buy
8,925,642
+50,448
+0.6% +$836K ﹤0.01% 1899
2025
Q4 		$168M Buy
8,875,194
+2,112,608
+31% +$30.3M ﹤0.01% 1790
2025
Q3 		$62.5M Sell
6,762,586
-46,112
-0.7% -$479K ﹤0.01% 2370
2025
Q2 		$77.6M Sell
6,808,698
-1,177,195
-15% -$12.7M ﹤0.01% 2213
2025
Q1 		$94.9M Buy
7,985,893
+310,221
+4% +$5.19M ﹤0.01% 2018
2024
Q4 		$145M Buy
7,675,672
+494,137
+7% +$11.3M ﹤0.01% 1856
2024
Q3 		$161M Buy
7,181,535
+361,520
+5% +$8.19M ﹤0.01% 1784
2024
Q2 		$142M Buy
6,820,015
+2,239,601
+49% +$34.9M ﹤0.01% 1824
2024
Q1 		$67.3M Sell
4,580,414
-63,322
-1% -$681K ﹤0.01% 2280
2023
Q4 		$47.9M Buy
4,643,736
+125,182
+3% +$858K ﹤0.01% 2500
2023
Q3 		$35.5M Sell
4,518,554
-823
-0% -$7.51K ﹤0.01% 2612
2023
Q2 		$45.1M Buy
4,519,377
+228,237
+5% +$2.33M ﹤0.01% 2543
2023
Q1 		$38.1M Buy
4,291,140
+148,612
+4% +$1.55M ﹤0.01% 2629
2022
Q4 		$45.5M Buy
4,142,528
+419,438
+11% +$5.06M ﹤0.01% 2537
2022
Q3 		$48.5M Buy
3,723,090
+367,743
+11% +$5.82M ﹤0.01% 2455
2022
Q2 		$42.5M Buy
3,355,347
+830,704
+33% +$9.42M ﹤0.01% 2600
2022
Q1 		$35.4M Sell
2,524,643
-23,218
-0.9% -$412K ﹤0.01% 2789
2021
Q4 		$73.8M Buy
2,547,861
+64,288
+3% +$1.95M ﹤0.01% 2404
2021
Q3 		$74.4M Buy
2,483,573
+396,957
+19% +$12.3M ﹤0.01% 2399
2021
Q2 		$55.4M Buy
2,086,616
+269,927
+15% +$7.92M ﹤0.01% 2631
2021
Q1 		$56.5M Buy
1,816,689
+646,715
+55% +$24.5M ﹤0.01% 2541
2020
Q4 		$38.5M Buy
1,169,974
+500,176
+75% +$16.6M ﹤0.01% 2629
2020
Q3 		$23.4M Buy
+669,798
New +$16.9M ﹤0.01% 2772

Other funds holding NRIX

VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock's NRIX Position: Q2 2026 in Review

BlackRock reduced its Nurix Therapeutics (NRIX) stake by 1.7% in Q2 2026, selling an estimated $2.65M and leaving 8,770,349 shares worth $213M. The position accounts for ﹤0.01% of the portfolio, ranked #1761.

BlackRock first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • BlackRock held 8,770,349 shares of Nurix Therapeutics worth $213M as of Q2 2026.
  • BlackRock sold 155,293 Nurix Therapeutics shares in Q2 2026, an estimated $2.65M.
  • Nurix Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1761 holding.
  • BlackRock first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.